

39 **Abstract**

40 Terazosin is an α_1 -adrenergic receptor antagonist that enhances glycolysis and increases cellular ATP by
41 binding to the enzyme phosphoglycerate kinase 1 (PGK1). Recent work has shown that terazosin is
42 protective against motor dysfunction in rodent models of Parkinson's disease (PD) and is associated with
43 slowed motor symptom progression in PD patients. However, PD is also characterized by profound
44 cognitive symptoms. We tested the hypothesis that terazosin protects against cognitive symptoms
45 associated with PD. We report two main results. First, in rodents with ventral tegmental area (VTA)
46 dopamine depletion modeling aspects of PD-related cognitive dysfunction, we found that terazosin
47 preserved cognitive function and produced a non-statistically significant trend towards protected VTA
48 tyrosine hydroxylase levels. Second, we found that after matching for demographics, comorbidities, and
49 disease duration, PD patients newly started on terazosin, alfuzosin, or doxazosin had a lower hazard of
50 being diagnosed with dementia compared to tamsulosin, an α_1 -adrenergic receptor antagonist that does
51 not enhance glycolysis. Together, these findings suggest that in addition to slowing motor symptom
52 progression, glycolysis-enhancing drugs protect against cognitive symptoms of PD.

53 INTRODUCTION

54 Parkinson's disease (PD) is a devastating neurodegenerative disease with motor and cognitive
55 symptoms (Dauer & Przedborski, 2003). A key risk factor for PD is impaired energy metabolism
56 (Saxena, 2012; Wellstead & Cloutier, 2011). We have recently found that the glycolysis-enhancing drug
57 terazosin increases energy metabolism in rodent models and in PD patients (Cai et al., 2019; Schultz et
58 al., 2022). We have also found that terazosin protects against motor neurodegeneration in the MPTP (1-
59 methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model, the 6-hydroxydopamine (6-OHDA) rat model,
60 as well as synuclein-overexpressing mice (Cai et al., 2019). Strikingly, analysis of the Progression
61 Markers Initiative (PPMI) database shows that terazosin is also associated with slowed motor symptom
62 progression in human PD patients (Cai et al., 2019). Furthermore, based on data from large administrative
63 databases, it protects against developing PD (Sasane et al., 2021; Simmering et al., 2021). Notably,
64 patients taking terazosin had fewer cognitive complications, as indexed by International Classification of
65 Diseases (ICD) codes (Cai et al., 2019). Despite these data, it is unclear whether terazosin is
66 neuroprotective for cognitive manifestations of PD.

67 One challenge is that there are few rodent models of cognitive dysfunction in PD. Human
68 cognition is complex and spans multiple behavioral repertoires such as planning and reasoning, which are
69 challenging to model in rodents. We have found that PD patients with cognitive dysfunction have
70 increased variability during interval timing, which involves estimating an interval of several seconds
71 (Parker et al., 2015; Singh et al., 2021). Specifically, PD patients with cognitive dysfunction have higher
72 interval timing variability compared to PD patients with preserved cognitive function. Because interval
73 timing can be readily studied in rodents (Buhusi & Meck, 2005), and work from our group has
74 demonstrated that interval timing is reliably impaired with disrupted ventral tegmental area (VTA)
75 dopamine (Kim et al., 2017; Kim & Narayanan, 2018; Narayanan et al., 2012; Parker et al., 2015),
76 interval timing provides an opportunity to investigate cognitive deficits in PD rodent models as a function
77 of terazosin.

78 In this study, we tested the hypothesis that terazosin protects against cognitive symptoms
79 associated with PD. We found that rodents with VTA dopamine depletion via 6-OHDA injections had
80 higher interval timing variability, similar to PD patients with cognitive dysfunction. Subsequently, we
81 found that mice receiving daily terazosin delivered in drinking water had decreased interval timing
82 variability and marginally more tyrosine hydroxylase-positive (TH+) immunofluorescence in the VTA.
83 Since terazosin is prescribed to human PD patients, we were able to combine these results with an
84 investigation of the association between clinically prescribed terazosin and cognitive symptoms in PD in
85 the IBM MarketScan administrative database. We found that human PD patients taking terazosin or
86 related glycolysis-enhancing medications had less risk of developing dementia compared to propensity-
87 score-matched patients taking tamsulosin, an α_1 -adrenergic receptor antagonist that does not enhance
88 glycolysis. Together, these data provide evidence that terazosin protects against cognitive symptoms, as
89 well as motor symptoms, associated with PD.

90

91 **RESULTS**

92 ***VTA 6-OHDA increases interval timing variability***

93 We trained 29 mice starting at ~14–16 weeks of age to perform an interval timing task in which
94 mice switched from one nosepoke to another based on internal timing cues to get a food reward (Fig. 1A;
95 Balci et al., 2008; Bruce et al., 2021; Larson et al., 2022). In these animals, we surgically injected vehicle
96 (0.03% ascorbic acid) as a surgical control or 6-OHDA to deplete dopamine in the VTA, which we have
97 previously shown impairs interval timing (Kim et al., 2017; Narayanan et al., 2012; Parker et al., 2015).
98 We began treatment with terazosin or vehicle (dimethyl sulfoxide; DMSO) immediately and tested
99 performance in the interval timing switch task approximately 16 days post-surgery. We normalized post-
100 surgical behavior in the switch task to pre-surgery behavior to determine magnitude change in behavior as
101 a result of VTA dopamine depletion and terazosin treatment. In VTA 6-OHDA mice treated with vehicle,
102 we found no significant change in median switch time (Vehicle DMSO: 103% (93%–117%; relative to
103 presurgical baseline) vs 6-OHDA DMSO: 92% (83%-105%) ; Wilcoxon $p = 0.12$; Cohen's $d = 0.66$), but
104 increased timing variability as measured by the coefficient of variability (CV) relative to Vehicle DMSO
105 controls (Vehicle DMSO: 93% (86%–104%) vs 6-OHDA DMSO: 118% (116%–123%); Wilcoxon $p <$
106 0.05 ; Cohen's $d = 1.66$; Fig. 2B–C). There were no changes in the number of switch trials performed
107 (Vehicle DMSO: 30 (18–44) vs 6-OHDA DMSO: 38 (30–45); Wilcoxon $p = 0.60$; Cohen's $d = 0.23$, data
108 not shown) or total number of rewards obtained during short and switch trials (Vehicle DMSO: 102 (95–
109 124) vs 6-OHDA DMSO: 106 (88–155); Wilcoxon $p = 0.96$; Cohen's $d = 0.27$, data not shown). These
110 results were similar to the increased interval timing CV observed in PD patients associated with cognitive
111 dysfunction (Singh et al., 2020) and provide evidence that VTA dopamine depletion models aspects of
112 cognitive dysfunction in human PD patients.

113

114 ***Terazosin protects against VTA 6-OHDA timing deficits.***

115 Terazosin is neuroprotective in preclinical rodent models of PD-related motor dysfunction (Cai et
116 al., 2019). We investigated whether terazosin protects against the effects of VTA 6-OHDA in interval

117 timing. Strikingly, we found that VTA dopamine-depleted mice treated with terazosin had decreased
118 interval timing variability relative to VTA 6-OHDA mice treated with vehicle (6-OHDA DMSO: 118%
119 (116%–123%) vs 6-OHDA terazosin: 97% (88%–108%); Wilcoxon $p < 0.05$; Cohen's $d = 1.53$), but no
120 change in median switch time (6-OHDA DMSO: 92% (83%–105%) vs 6-OHDA terazosin: 101% (92%–
121 106%); Wilcoxon $p = 0.40$; Cohen's $d = 0.35$; Fig. 2a–c). There were no changes in the number of switch
122 trials performed (6-OHDA DMSO: 38 (30–45) vs 6-OHDA terazosin: 25 (16–51); Wilcoxon $p = 0.68$;
123 Cohen's $d = 0.09$, data not shown) or total number of rewards obtained during short and switch trials (6-
124 OHDA DMSO: 106 (88–155) vs 6-OHDA terazosin: 113 (97–128); Wilcoxon $p = 1.0$; Cohen's $d = 0.07$,
125 data not shown). These data support our hypothesis that terazosin is protective in rodents modeling
126 aspects of cognitive dysfunction in PD.

127 We also examined the levels of TH+ immunofluorescence in the VTA as an indirect measure of
128 dopamine depletion (Fig. 3a), since terazosin has been shown to protect substantia nigra TH levels in rats
129 (Cai et al., 2019) VTA 6-OHDA mice had markedly decreased TH+ fluorescence in the VTA (Vehicle
130 DMSO: 1776 (1577–2010) arbitrary units (AU) vs 6-OHDA DMSO: 673 (623–779) AU; Wilcoxon $p <$
131 0.05 ; Cohen's $d = 3.07$; Fig. 3b). Interestingly, we found a non-statistically significant trend for increased
132 TH+ fluorescence in the VTA of dopamine-depleted mice treated with terazosin relative to DMSO (6-
133 OHDA DMSO: 673 (623–779) vs 6-OHDA terazosin: 1071 (653–1094); Wilcoxon $p = 0.09$; Cohen's $d =$
134 0.79 ; Fig. 3b), suggesting that terazosin tended to protect TH+ neurons in the VTA of dopamine-depleted
135 mice. This effect of terazosin is similar to that observed previously (Cai et al., 2019). To establish a
136 relationship between the change in VTA TH+ immunofluorescence and behavioral results, we correlated
137 fluorescence values with changes in switch time CV following surgery and DMSO or terazosin treatment.
138 We observed that VTA TH+ fluorescence in all DMSO-treated mice had a strong and significant negative
139 correlation with changes in switch time CV, such that greater VTA TH+ fluorescence values were related
140 to lower switch time CV ($r = -0.59$; $p < 0.05$); there was also a similar non-significant relationship
141 between switch time CV and VTA TH+ fluorescence values in dopamine-depleted mice treated with
142 terazosin ($r = -0.47$; $p = 0.15$; Fig. 3c).

143

144 ***TZ protects against cognitive symptoms of PD***

145 An analysis of patient databases was used to determine whether glycolysis-enhancing terazosin,
146 alfuzosin, or doxazosin (TZ/AZ/DZ) is associated with lower hazard of developing dementia compared to
147 tamsulosin. We identified 14,184 men with PD who had not taken TZ/DZ/AZ or tamsulosin previously.
148 After matching for demographics, comorbidities, and disease duration, 1508 men (754 matched pairs)
149 remained. This matching successfully reduced imbalance between the groups (Supplemental Table S1).
150 After matching, the reduction was a statistically significant 25% reduction (HR = 0.75; 95% CI: 0.57,
151 0.98) in the hazard of being diagnosed with dementia (Fig. 4).

152

153 **DISCUSSION**

154 We tested the hypothesis that the glycolysis-enhancing drug terazosin is protective against
155 cognitive dysfunction associated with PD. We found that VTA dopamine-depleted mice had increased
156 interval timing variability, modeling cognitive deficits seen in PD patients. Rodents with VTA dopamine
157 depletion and terazosin had preserved interval timing variability and a trend toward more VTA TH+
158 fluorescence compared to dopamine-depleted mice treated with vehicle. Finally, analysis of patient
159 databases revealed that PD patients newly started on terazosin had less risk of developing dementia
160 compared to PD patients taking tamsulosin, an α_1 -adrenergic receptor antagonist that does not impact
161 glycolysis. Together these data provide evidence that terazosin is protective for cognitive, as well as
162 motor, symptoms of PD. This is key as there are only a few minimally effective treatments for PD-related
163 cognitive symptoms and no treatments that alter disease course.

164 Increased interval timing variability models some aspects of cognitive dysfunction in PD and
165 Alzheimer's disease patients (Gür et al., 2020; Kim et al., 2017; Larson et al., 2022; Parker et al., 2015;
166 Singh et al., 2021). Importantly, the VTA is involved in PD and degenerates through the course of the
167 disease (Alberico et al., 2015). Accordingly, we observed that VTA dopamine depletion increased
168 interval timing variability, and terazosin reversed or prevented deficits. Furthermore, we found a non-
169 statistically significant trend for more TH+ fluorescence in VTA dopamine-depleted mice treated with
170 terazosin compared to those treated with DMSO alone. The level of VTA TH+ fluorescence correlates
171 with interval timing variability (Gür et al., 2020). However, this correlation does not hold for VTA
172 dopamine-depleted treated with terazosin as this treatment likely changed the relationship between VTA
173 TH+ fluorescence and interval timing variability. Further, it is possible that terazosin might increase
174 synaptic dopamine in the projection fields of VTA dopamine neurons, as was observed in nigrostriatal
175 dopamine terminals (Cai et al., 2019). Our data establish that VTA dopamine depletion models PD-like
176 increased interval timing variability, which is protected by terazosin.

177 From analysis of patient databases, we previously showed that terazosin is associated with fewer
178 PD diagnostic codes linked with cognition, relative to tamsulosin (Cai et al., 2019). Here, we expand this

179 finding and show that PD patients have less risk of developing dementia relative to patients taking
180 tamsulosin. Because these data are derived from large administrative databases, it is difficult to discern
181 whether these patients had interval timing deficits.

182 Our work has several limitations. First, there is no definitive rodent model of cognitive
183 dysfunction in PD, in part because the underlying pathophysiology is complex and diverse. However, our
184 model of VTA dopamine depletion models at least one characteristic of cognitive dysfunction in PD.
185 Second, the mechanistic link between enhanced glycolysis and protection of dopamine neurons, dopamine
186 release, or TH levels and/or production is unclear. However, it is possible that terazosin is protecting
187 against VTA 6-OHDA-induced cell death or enhancing TH or dopamine similar to that observed in the
188 nigrostriatal pathway (Cai et al., 2019). This is an important future direction to understand how
189 glycolysis-enhancing therapeutics can modulate neurodegenerative disease. Third, our data from terazosin
190 are retrospectively observational and depend on comparisons with tamsulosin (Gros et al., 2021; Sasane et
191 al., 2021; Simmering et al., 2021).

192 These data converge with our prior work on motor symptoms of PD and provide evidence that
193 terazosin is protective not only for neurons in the substantia nigra, but also in the ventral tegmental area
194 (Alberico et al., 2015; Cai et al., 2019). Future studies will rigorously test this idea with a prospective and
195 placebo-controlled randomized trial, in which motor and cognitive aspects of PD are carefully measured,
196 and with cellular, molecular, and preclinical studies to understand how enhancing glycolysis modulates
197 brain circuits.

198

199 MATERIALS AND METHODS

200 **Mice:** All experimental procedures were performed in accordance with the relevant guidelines of
201 Protocol #0062039 and with the approval of the Institutional Animal Care and Use Committee (IACUC)
202 at the University of Iowa. Wild-type male and female C57BL/6 mice were received from Jackson Labs
203 (Bar Harbor, ME) at approximately 12–14 weeks of age and acclimated to the animal holding facility for
204 2 weeks. During acclimation, all mice were communally housed on a 12-hour light/dark cycle with *ad lib*
205 access to laboratory rodent chow and water. To facilitate operant behavioral training (described below),
206 mice were individually housed, weighed daily, and maintained on a restricted diet with *ad lib* access to
207 water.

208
209 **Interval Timing Switch Task:** The interval timing switch task is designed to capture an animal's
210 internal representation of time (Balci et al., 2008; Bruce et al., 2021; Larson et al., 2022; Tosun et al.,
211 2016), as in other interval timing tasks (Emmons et al., 2020; Narayanan et al., 2012). Mice are trained to
212 switch from a short to a long nosepoke after approximately 6 seconds. This switch is an explicit time-
213 based decision that requires working memory for temporal rules and attention to the passage of time, and
214 models cognitive deficits in neurodegenerative disease (Gür et al., 2020; Larson et al., 2022; Parker et al.,
215 2015; Singh et al., 2021).

216 Briefly, mice were trained in standard operant chambers enclosed in sound-attenuated cabinets
217 (MedAssociates, St. Albans, VT) that contained two light-equipped nosepoke response ports (left and
218 right) on the front wall, a reward hopper located between the two nosepoke response ports, and another
219 light-equipped nosepoke on the back wall, opposite the reward hopper. Operant training began by shaping
220 the animal's behavior. Trial initiation began with a response at the back nosepoke, at which point either
221 the left or right front nosepoke was illuminated, and a response at the appropriate port resulted in a
222 reward. Mice were then advanced to the interval timing switch protocol, in which each session was
223 randomly organized into 50% short (6 seconds) and 50% long (18 seconds) trials. Either the left or right
224 nosepoke was designated for short trials and the contralateral nosepoke for long trials (counterbalanced

225 across experimental groups). A back nosepoke response initiated a trial, generating two identical light
226 cues above the left and right nosepokes, along with an 8-kHz tone (72 dB) for both trial types. In short
227 trials mice received a reward after 6 seconds for the first response at the designated nosepoke. In long
228 trials, mice would begin by responding at the short-trial-designated nosepoke. When there was no
229 reinforcement after 6 seconds, the mouse would switch to the long-trial-designated nosepoke until a
230 reward was delivered after 18 seconds. Once mice were performing optimally, they were taken off food
231 restriction and underwent stereotaxic surgical procedures (outlined below). Behavioral changes were
232 assessed by retraining the mice in the same interval timing switch task. Only long switch trials were
233 analyzed during both training periods.

234

235 **Surgical Procedures:** On the day of surgery, 6-hydroxydopamine hydrobromide (6-OHDA;
236 Millipore Sigma #162957, Darmstadt, Germany) and desipramine hydrochloride (Millipore Sigma
237 #D3900) were freshly made and stored on ice away from light. 6-OHDA was prepared at 2 mg/ml in
238 0.03% ascorbic acid (AA) and desipramine at 4 mg/ml in 0.9% saline. Mice were anesthetized under
239 4.0% isoflurane at 400 ml/min, and surgical levels of isoflurane (1.5%–3.0%) were maintained at
240 approximately 120 ml/min (SomnoSuite, Kent Scientific, Torrington, CT, USA). Desipramine (25 mg/kg)
241 was injected intraperitoneally (IP) to protect norepinephrine terminals against 6-OHDA (Thiele et al.,
242 2012; Torres & Dunnett, 2012). An incision was made along midline and bilateral craniotomies drilled
243 above the VTA (AP -3.3, ML +/-1.1). Mice were randomly assigned to three different groups: 1)
244 midbrain vehicle injections treated with dimethyl sulfoxide (DMSO; Vehicle DMSO); 2) VTA dopamine
245 depletion treated with DMSO (6-OHDA DMSO); and 3) VTA dopamine depletion treated with terazosin
246 (6-OHDA terazosin). The vehicle group received microinjections of 0.5 μ l 0.03% AA bilaterally, and the
247 dopamine-depletion groups received equal volumes of 6-OHDA prepared in AA (AP -3.3, ML +/-1.1, DV
248 -4.6 at 10° laterally). Vehicle or 6-OHDA was infused over 10 minutes (0.05 μ l/min; Legato 130 Syringe
249 Pump, kd Scientific, Holliston, MA, USA), with a 5-minute wait period before removing the needle. After
250 the incision was closed, mice were moved to a clean cage with *ad lib* access to food and either DMSO- or

251 terazosin-treated water (described below). All mice recovered for one week before transitioning back to
252 the interval timing switch task for approximately 3–4 weeks of post-surgical behavioral training.

253

254 **Mouse terazosin:** Following surgery, terazosin (Tocris #1506, Minneapolis, MN) prepared in
255 DMSO was delivered through *ad lib* access to treated water. Water for control mice was made with
256 equivalent volumes of DMSO alone. Preparation of terazosin began with a 100-mM stock solution (42
257 mg/ml in DMSO) stored at -80 °C. The stock was diluted 1:100 to make a 1-mM (0.42 µg/µl in water)
258 working solution. We added 106 µL of working solution, equating to 45 µg terazosin (0.42 µg/µl x 106
259 µl), to 300 ml water, to which mice had free access. The concentration of the final drinking water was
260 0.15 µg/ml terazosin (45 µg/300 ml). An average mouse drinks approximately 5 ml of water per day
261 (Nicolaus et al., 2016), so each mouse consumed ~0.75 µg terazosin daily (0.15 µg/ml x 5 ml/day).
262 Additionally, experimental mice weigh on average 0.025 kg (Nicolaus et al., 2016); thus, the terazosin
263 dose received by our animals was ~0.03 mg/kg/day (0.75 µg/day/0.025 kg). All terazosin- and DMSO-
264 treated water was replaced every 2 days for the duration of the experiment post-surgery (Cai et al., 2019).

265

266 **Histology:** Mice were anesthetized with ketamine (100 mg/kg IP) and xylazine (10 mg/kg IP) and
267 transcardially perfused with cold phosphate-buffered saline (PBS) and 4% paraformaldehyde (PFA).
268 Brains were removed and post-fixed in 4% PFA overnight, followed by immersion in 30% sucrose for
269 approximately 48 hours. The fixed brains were sliced at 40-µm coronal sections of the midbrain, using a
270 cryostat (Leica Biosystems, Deer Park, IL). Sections were then blocked for one hour in 5% normal goat
271 serum (NGS) in PBST (0.3% Triton X-100 in 1x PBS). After blocking, sections were incubated overnight
272 at 4 °C in rabbit anti-tyrosine hydroxylase polyclonal antibody (Abcam #ab6211, Cambridge, UK) diluted
273 to 1:1000 in 5% NGS. The sections were washed with PBST three times over 30 minutes before a 2-hour
274 incubation in goat anti-rabbit IgG (H+L) Alexa Fluor 568 secondary antibody (Invitrogen #A-11036,
275 Waltham, MA) diluted to 1:1000 in 5% NGS. After three more PBST washes, the sections were mounted

276 with ProLong Diamond Antifade Mountant with DAPI (Invitrogen #P36962) on Superfrost microscope
277 slides (Fisher Scientific, Waltham, MA).

278 Brain sections were imaged using an Olympus VS120 microscope (Olympus, Center Valley, PA).
279 Histological targeting of the VTA was confirmed by two independent authors, one blinded to treatment
280 conditions. Eight mice, in which the injection missed the VTA, were excluded. For the remaining mice,
281 the Count and Measure analysis tool in CellSens Dimension Desktop (Olympus, Shinjuku, Tokyo, Japan)
282 was used to quantify tyrosine hydroxylase (TH) fluorescence levels in the VTA. Fluorescence levels in
283 each animal were determined by averaging the mean pixel intensities of three VTA sections. Anterior-
284 posterior coordinates of the VTA were determined following prior literature and ranged from -3.1 to -3.5,
285 respectively. Outlines of the regions of interest were referenced from Franklin & Paxinos, 2008.

286
287 **Statistics:** We analyzed effects of dopamine depletion and terazosin using a generalized linear
288 model (*lm* in R). Post-hoc comparisons were performed using estimated marginal means (*emmeans* in R)
289 and Tukey's correction for multiple comparisons. Four-to-five sessions of interval timing behavior were
290 collected and analyzed per mouse, both before surgery and approximately 16 days post-surgery. Switch
291 time coefficients of variability (CV) and mean switch times were normalized to each mouse's pre-surgical
292 baseline to account for animal-specific variability in timing behavior. All statistics was reviewed by the
293 Biomedical Epidemiology Research and Design core in the Institute for Clinical and Translational
294 Sciences at the University of Iowa.

295
296 **Administrative Database Search:** Using the IBM MarketScan Commercial Claims and
297 Encounters and the Medicare Coordination of Benefits databases of health insurance claims, we identified
298 men aged 40 or older taking terazosin, alfuzosin, or doxazosin (collectively, TZ/DZ/AZ) or tamsulosin,
299 not in conjunction with finasteride or dutasteride. Men who switched between the TZ/DZ/AZ and
300 tamsulosin classes were excluded. To ensure that we identified men who were newly started on
301 TZ/DZ/AZ or Tamsulosin, we required: 1) at least 12 months of enrollment prior to the observed first

302 dispensing date with prescription drug coverage; 2) at least two dispensing events to occur in the first year
303 following the first dispensing date; 3) the PD diagnosis date must have occurred before the TZ/DZ/AZ or
304 tamsulosin start date; and 4) the men must have been free of a dementia diagnosis (ICD-9-CM: 289.9,
305 290.0, 290.1, 290.2, 290.3, 290.4, 290.43, 294.1, 294.8, 331.0, 331.1, 348.3 or ICD-10-CM: F01.51,
306 F03.90, F05, F06.0, F06.8, F29) at start of medication. To ensure that we identified new cases of PD, the
307 first observed diagnosis of PD or dispensing of levodopa must have occurred within at least 12 months of
308 TZ/DZ/AZ or tamsulosin start date; health insurance claims data do not include detailed measures of PD
309 severity, e.g., Unified Parkinson's Disease Rating Scale scores or cognitive function. The administrative
310 database search and subsequent analysis described below was performed on a fully deidentified secondary
311 database and was therefore exempt from institutional review board approval.

312
313 **Administrative Database Analysis:** Men taking TZ/DZ/AZ were matched to men taking
314 tamsulosin in a two-stage process. First, we estimated a propensity score model incorporating the
315 following criteria: age; health care utilization during the lookback period (rate of hospitalization, rate of
316 outpatient encounters); baseline health status (mean number of diagnoses per outpatient encounter, rate of
317 unique outpatient diagnoses, the 29 Elixhauser comorbidities); factors for prescribing decision (diagnosis
318 of benign prostatic hyperplasia, diagnosis of slow urinary stream, diagnosis of abnormal prostate-specific
319 antigen (PSA), diagnosis of orthostatic hypotension, diagnosis of other hypotension, procedural claim for
320 testing PSA, procedural claim for a uroflow study, procedural claim for a cystometrogram); and
321 medication start date. The propensity score model was estimated using a boosted tree with the depth and
322 number of rounds selected by testing performance on a 25% held-out validation set. Once the depth and
323 number of rounds were selected, we used the entire data set to generate and estimate the propensity score
324 model. Second, we required the time between the diagnosis of PD and the medication start date to be +/-
325 180 days between possible matches. This was done to ensure a similar duration of disease and to
326 potentially reduce unobserved heterogeneity due to differing PD severity. Within the set of possible
327 matches based on the time between PD diagnosis and the medication start date, we selected the nearest

328 possible match based on the log odds estimated by our propensity score model. We imposed a 20%
329 pooled standard deviation caliper to exclude poor matches. After matching, we followed the medical
330 records of men for 8 years to track the rates of developing dementia. We compared the hazard of
331 developing dementia with Kaplan Meier survival curves and Cox proportional hazards regression.
332 Standard errors were clustered to account for the propensity score matching.

333 **ACKNOWLEDGEMENTS**

334 The Truven database was provided by the University of Iowa. This work was supported by a
335 faculty fellowship through the Iowa Neuroscience Institute to JES and NIH R01s MH116043, NS120987
336 to NSN.

337

338 **DATA AVAILABILITY**

339 All code and raw data are available at <https://narayanan.lab.uiowa.edu>.

340

341 **AUTHOR CONTRIBUTIONS**

342 MAW, KS, and NSN designed the animal experiments. JES and NSN designed the human PD
343 database analysis. MAW, KS, and MO performed all animal experiments. MAW and KS independently
344 verified histological targeting. EET, KS, and GMA performed histological immunofluorescent analysis.
345 MAW, KS, and QZ maintained and delivered terazosin. MAW, KS, JES, and NSN performed all
346 statistical analyses. MAW, KS, JES and NSN wrote the manuscript, and all authors reviewed and revised
347 the manuscript.

348

349 **COMPETING INTERESTS**

350 The authors declare that there are no conflicts of interest.

351 **REFERENCES**

- 352 Alberico, S. L., Cassell, M. D., & Narayanan, N. S. (2015). The vulnerable ventral tegmental area in
353 Parkinson's disease. *Basal Ganglia*, 5(2–3), 51–55. <https://doi.org/10.1016/j.baga.2015.06.001>
- 354 Balci, F., Papachristos, E. B., Gallistel, C. R., Brunner, D., Gibson, J., & Shumyatsky, G. P. (2008).
355 Interval timing in genetically modified mice: A simple paradigm. *Genes, Brain and Behavior*,
356 7(3), 373–384. <https://doi.org/10.1111/j.1601-183X.2007.00348.x>
- 357 Bruce, R. A., Weber, M. A., Volkman, R. A., Oya, M., Emmons, E. B., Kim, Y., & Narayanan, N. S.
358 (2021). Experience-related enhancements in striatal temporal encoding. *The European Journal of*
359 *Neuroscience*, 54(3), 5063–5074. <https://doi.org/10.1111/ejn.15344>
- 360 Buhusi, C. V., & Meck, W. H. (2005). What makes us tick? Functional and neural mechanisms of interval
361 timing. *Nature Reviews. Neuroscience*, 6(10), 755–765. <https://doi.org/10.1038/nrn1764>
- 362 Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A.,
363 Polgreen, P. M., Narayanan, N. S., Yuan, Y., Chen, Z., Su, W., Han, Y., Zhao, C., Gao, L., Ji, X.,
364 Welsh, M. J., & Liu, L. (2019). Enhancing glycolysis attenuates Parkinson's disease progression
365 in models and clinical databases. *The Journal of Clinical Investigation*, 129(10), 4539–4549.
366 <https://doi.org/10.1172/JCI129987>
- 367 Dauer, W., & Przedborski, S. (2003). Parkinson's Disease: Mechanisms and Models. *Neuron*, 39(6), 889–
368 909. [https://doi.org/10.1016/S0896-6273\(03\)00568-3](https://doi.org/10.1016/S0896-6273(03)00568-3)
- 369 Emmons, E., Tunes-Chiuffa, G., Choi, J., Bruce, R. A., Weber, M. A., Kim, Y., & Narayanan, N. S.
370 (2020). Temporal Learning Among Prefrontal and Striatal Ensembles. *Cerebral Cortex*
371 *Communications*, 1(1), tgaa058. <https://doi.org/10.1093/texcom/tgaa058>
- 372 Franklin, K. B. J., & Paxinos, G. (2008). *The mouse brain in stereotaxic coordinates* (Compact 3. ed).
373 Elsevier Academic Press.
- 374 Gros, P., Wang, X., Guan, J., Lang, A. E., Austin, P. C., Welk, B., Visanji, N. P., & Marras, C. (2021).
375 Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.

- 376 *Movement Disorders: Official Journal of the Movement Disorder Society*, 36(10), 2419–2425.
377 <https://doi.org/10.1002/mds.28712>
- 378 Gür, E., Duyan, Y. A., Arkan, S., Karson, A., & Balci, F. (2020). Interval timing deficits and their
379 neurobiological correlates in aging mice. *Neurobiology of Aging*, 90, 33–42.
380 <https://doi.org/10.1016/j.neurobiolaging.2020.02.021>
- 381 Kim, Y.-C., Han, S.-W., Alberico, S. L., Ruggiero, R. N., De Corte, B., Chen, K.-H., & Narayanan, N. S.
382 (2017). Optogenetic Stimulation of Frontal D1 Neurons Compensates for Impaired Temporal
383 Control of Action in Dopamine-Depleted Mice. *Current Biology*, 27(1), 39–47.
384 <https://doi.org/10.1016/j.cub.2016.11.029>
- 385 Kim, Y.-C., & Narayanan, N. S. (2018). Prefrontal D1 Dopamine-Receptor Neurons and Delta Resonance
386 in Interval Timing. *Cerebral Cortex (New York, N.Y. : 1991)*.
387 <https://doi.org/10.1093/cercor/bhy083>
- 388 Larson, T., Khadelwal, V., Weber, M. A., Leidinger, M. R., Meyerholz, D. K., Narayanan, N. S., &
389 Zhang, Q. (2022). *Mice expressing P301S mutant human tau have deficits in interval timing*
390 [Preprint]. Neuroscience. <https://doi.org/10.1101/2022.04.04.487032>
- 391 Narayanan, N. S., Land, B. B., Solder, J. E., Deisseroth, K., & DiLeone, R. J. (2012). Prefrontal D1
392 dopamine signaling is required for temporal control. *Proceedings of the National Academy of*
393 *Sciences of the United States of America*, 109(50), 20726–20731.
394 <https://doi.org/10.1073/pnas.1211258109>
- 395 Nicolaus, M. L., Bergdall, V. K., Davis, I. C., & Hickman-Davis, J. M. (2016). Effect of Ventilated
396 Caging on Water Intake and Loss in 4 Strains of Laboratory Mice. *Journal of the American*
397 *Association for Laboratory Animal Science: JAALAS*, 55(5), 525–533.
- 398 Parker, K. L., Chen, K.-H., Kingyon, J. R., Cavanagh, J. F., & Narayanan, N. S. (2015). Medial frontal ~4
399 Hz activity in humans and rodents is attenuated in PD patients and in rodents with cortical
400 dopamine depletion. *Journal of Neurophysiology*, jn.00412.2015.
401 <https://doi.org/10.1152/jn.00412.2015>


- 402 Sasane, R., Bartels, A., Field, M., Sierra, M. I., Duvvuri, S., Gray, D. L., Pin, S. S., Renger, J. J., & Stone,
403 D. J. (2021, April 6). *Parkinson disease among patients treated for benign prostatic hyperplasia*
404 *with $\alpha 1$ adrenergic receptor antagonists*. American Society for Clinical Investigation.
405 <https://doi.org/10.1172/JCI145112>
- 406 Saxena, U. (2012). Bioenergetics failure in neurodegenerative diseases: Back to the future. *Expert*
407 *Opinion on Therapeutic Targets*, 16(4), 351–354. <https://doi.org/10.1517/14728222.2012.664135>
- 408 Schultz, J. L., Brinker, A. N., Xu, J., Ernst, S. E., Tayyari, F., Rauckhorst, A. J., Liu, L., Uc, E. Y.,
409 Taylor, E. B., Simmering, J. E., Magnotta, V. A., Welsh, M. J., & Narayanan, N. S. (2022). A
410 pilot to assess target engagement of terazosin in Parkinson’s disease. *Parkinsonism & Related*
411 *Disorders*, 94, 79–83. <https://doi.org/10.1016/j.parkreldis.2021.11.022>
- 412 Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., & Pottegård, A. (2021). Association of
413 Glycolysis-Enhancing α -1 Blockers With Risk of Developing Parkinson Disease. *JAMA*
414 *Neurology*. <https://doi.org/10.1001/jamaneurol.2020.5157>
- 415 Singh, A., Cole, R. C., Espinoza, A. I., Evans, A., Cao, S., Cavanagh, J. F., & Narayanan, N. S. (2021).
416 Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson’s disease.
417 *NPJ Parkinson’s Disease*, 7(1), 14. <https://doi.org/10.1038/s41531-021-00158-x>
- 418 Thiele, S. L., Warre, R., & Nash, J. E. (2012). Development of a unilaterally-lesioned 6-OHDA mouse
419 model of Parkinson’s disease. *Journal of Visualized Experiments: JoVE*, 60, 3234.
420 <https://doi.org/10.3791/3234>
- 421 Torres, E. M., & Dunnett, S. B. (2012). 6-OHDA Lesion Models of Parkinson’s Disease in the Rat. In E.
422 L. Lane & S. B. Dunnett (Eds.), *Animal Models of Movement Disorders: Volume I* (pp. 267–279).
423 Humana Press. https://doi.org/10.1007/978-1-61779-298-4_13
- 424 Tosun, T., Gür, E., & Balcı, F. (2016). Mice plan decision strategies based on previously learned time
425 intervals, locations, and probabilities. *Proceedings of the National Academy of Sciences*, 113(3),
426 787–792. <https://doi.org/10.1073/pnas.1518316113>

427 Wellstead, P., & Cloutier, M. (2011). An energy systems approach to Parkinson's disease. *WIREs Systems*

428 *Biology and Medicine*, 3(1), 1–6. <https://doi.org/10.1002/wsbm.107>


429

430 **FIGURES**



431

432 **Figure 1: Experimental design.** **a)** Experimental timeline. DMSO: dimethyl sulfoxide. **b)** Interval timing
433 switch task highlighting optimal performance during long trials. Trials are initiated at the back response
434 port. Identical cues are delivered for both short and long trials, which are randomly delivered. On short
435 trials, mice are rewarded for the first response after 6 seconds at the designated short nosepoke (left or
436 right). On long trials, mice start by responding at the designated short nosepoke. When there is no reward
437 after 6 seconds, mice switch to the designated long nosepoke (contralateral to designated short nosepoke)
438 and wait 18 seconds for reward delivery. This time to switch from the short to long nosepoke is a time-
439 based decision as in other interval timing tasks. Switch time is defined as the time of last response at the
440 short nosepoke before responses start at the long nosepoke, and only switch trials are analyzed.



441

442 **Figure 2: Interval timing variability improves in VTA dopamine-depleted mice treated with**

443 **terazosin. a)** Cumulative distribution function of switch times. **b)** Switch time coefficient of variability

444 (CV) and **c)** mean switch time. Data from 10 VTA Vehicle mice treated with dimethyl sulfoxide (DMSO;


445 in black), 8 VTA 6-hydroxydopamine (6-OHDA) mice treated with DMSO (in red), and 11 VTA 6-

446 OHDA mice treated with terazosin (TZ; in green). Each dot represents a single mouse, and the horizontal

447 line represents the median value. All data presented are approximately 16 days post-surgery and

448 normalized according to pre-surgical behavior. * $p < 0.05$.

449



450

451 **Figure 3: VTA tyrosine hydroxylase (TH) fluorescence levels correlate with interval timing**

452 **coefficient of variability.** **a)** Representative histological images of TH fluorescence (red) from VTA

453 Vehicle mice treated with dimethyl sulfoxide (DMSO; left), VTA 6-hydroxydopamine (6-OHDA) mice

454 treated with DMSO (middle), and VTA 6-OHDA mice treated with terazosin (TZ; right). **b)** VTA TH


455 fluorescence (in arbitrary units; AU) from 10 VTA Vehicle mice treated with DMSO (in black), 8 VTA 6-

456 OHDA mice treated with DMSO (in red), and 11 VTA 6-OHDA mice treated with terazosin (in green). *

457 $p < 0.05$. Each dot represents a single mouse, and the horizontal line represents the median value. **c)** In

458 VTA Vehicle and VTA 6-OHDA mice treated with DMSO, the percent change in coefficient of

459 variability (CV) relative to presurgical baseline is strongly correlated with VTA TH fluorescence (red and
460 black line). The relationship between VTA 6-OHDA and mice treated with terazosin is shown in green.
461



462

463 **Figure 4: Fraction of Parkinson's disease patients remaining dementia free in the Truven Database.**

464 Kaplan-Meier plot of 754 matched pairs of men aged 40 or older diagnosed with Parkinson's disease (PD)

465 and newly started on terazosin, alfuzosin, or doxazosin (green) or tamsulosin (red). The red and green

466 lines denote cumulative incidence of PD patients remaining dementia free, and the shaded areas denote

467 95% CI.

468

469 **Supplemental**

470
 471 **Table S1:** Cohort Summary Measures Before and After Matching. Values reported are median
 472 and inner quartile range for continuous variables or count and percent for binary variables. SMD
 473 is the standardized mean difference or Cohen’s *d*, a measure of effect size. Balance was obtained
 474 (absolute value of SMD <= 0.1) on nearly all measures included in the propensity score model or
 475 the disease duration.

Variable	Before Matching			After Matching		
	TZ/DZ/AZ (n = 875)	Tamsulosin (n = 4,756)	SMD	TZ/DZ/AZ	Tamsulosin	SMD
Demographics and Timing						
Age (years)	72 (63, 80)	74 (64, 81)	-0.08	72 (63, 80)	72 (62, 81)	0.01
RX Start Year	2003 (2001, 2006)	2004 (2001, 2008)	-0.02	2004 (2001, 2006)	2004 (2002, 2008)	0.01
Lookback (years)	3.8 (2.2, 6.4)	4.8 (2.7, 7.8)	-0.26	4.3 (2.5, 6.8)	3.9 (2.3, 6.0)	0.19
Follow-Up (years)	1.8 (0.9, 4.1)	2.0 (0.9, 2.8)	-0.01	2.0 (0.9, 4.2)	1.9 (0.9, 4.1)	0.00
PD Disease Duration (years)	2.35 (1.53, 3.99)	2.74 (1.72, 4.60)	-0.18	2.57 (1.68, 4.25)	2.47 (1.66, 3.97)	0.10
Baseline Healthcare Utilization						
Inpatient Visits Per Year	0.14 (0.00, 1.34)	0.35 (0.00, 1.67)	-0.10	0.25 (0.00, 1.41)	0.13 (0.00, 1.48)	-0.13
Outpatient Visits Per Year	17 (10, 27)	17 (10, 27)	-0.01	17 (11, 28)	16 (9, 27)	0.01
Mean Number of Unique DX	0.35 (0.20, 0.62)	0.31 (0.17, 0.57)	0.05	0.31 (0.19, 0.56)	0.36 (0.21, 0.60)	-0.08
Outpatient DX Code Incidence	22 (14, 38)	25 (15, 42)	-0.10	23 (14, 39)	22 (12, 38)	0.00
Elixhauser Comorbidities						
Alcohol Abuse	12 (1.4%)	117 (2.5%)	-0.07	12 (1.6%)	13 (1.7%)	-0.01
Anemia	219 (25.0%)	1,204 (25.3%)	-0.01	201 (26.7%)	177 (23.5%)	0.07
Blood Loss	18 (2.1%)	130 (2.7%)	-0.04	16 (2.1%)	15 (2.0%)	0.01
Heart Failure	156 (17.8%)	923 (19.4%)	-0.04	138 (18.3%)	144 (19.1%)	-0.02
Coagulopathy	50 (5.7%)	309 (6.5%)	-0.03	46 (6.1%)	32 (4.2%)	0.09
Depression	143 (15.3%)	841 (17.7%)	-0.06	127 (16.8%)	106 (14.1%)	0.08
Diabetes W/O Complications	312 (35.7%)	1,545 (32.5%)	0.07	287 (38.1%)	247 (32.8%)	0.11
Diabetes W/ Complications	146 (16.7%)	752 (15.8%)	0.02	134 (17.8%)	103 (13.7%)	0.11
Drug Abuse	8 (0.9%)	81 (1.7%)	-0.06	6 (0.8%)	19 (2.5%)	-0.14
Fluid/Electrolyte Disorders	160 (18.3%)	993 (20.9%)	-0.06	147 (19.5%)	138 (18.3%)	0.03
HIV	3 (0.3%)	7 (0.1%)	0.05	3 (0.4%)	1 (0.1%)	0.05
HTN W/O Complications	623 (71.2%)	3,310 (69.6%)	0.04	555 (73.6%)	528 (70.0%)	0.08
HTN W/ Complications	169 (19.3%)	875 (18.4%)	0.02	159 (21.1%)	134 (17.8%)	0.08
Hypothyroidism	97	641	-0.07	95	97	-0.01

	(11.1%)	(13.5%)		(12.6%)	(12.9%)	
Liver Disease	38 (4.3%)	210 (4.4%)	0.00	36 (4.8%)	29 (3.8%)	0.05
Lymphoma	20 (2.3%)	94 (2.0%)	0.02	20 (2.7%)	13 (1.7%)	0.06
Metastatic Cancer	14 (1.6%)	120 (2.5%)	-0.06	14 (1.9%)	18 (2.4%)	-0.04
Other Neurological Disorders	626 (71.5%)	3,788 (79.6%)	-0.20	548 (72.7%)	511 (67.8%)	0.11
Obesity	45 (5.1%)	381 (8.0%)	-0.11	44 (5.8%)	33 (4.4%)	0.07
Paralysis	39 (4.5%)	267 (5.6%)	-0.05	36 (4.8%)	29 (3.8%)	0.05
Pulmonary/Circ Disorders	38 (4.3%)	244 (5.1%)	-0.04	35 (4.6%)	42 (5.6%)	-0.04
Psychoses	94 (10.7%)	568 (11.9%)	-0.04	89 (11.8%)	81 (10.7%)	0.03
Peptic Ulcer Disease	2 (0.2%)	22 (0.5%)	-0.04	2 (0.3%)	3 (0.4%)	-0.02
COPD	256 (29.3%)	1,536 (32.3%)	-0.07	226 (30.0%)	220 (29.2%)	0.02
Peripheral Vascular Disease	205 (23.4%)	1,329 (27.9%)	-0.10	193 (25.6%)	179 (23.7%)	0.04
Renal Failure	124 (14.2%)	507 (10.7%)	0.11	117 (15.5%)	108 (14.3%)	0.03
Rheumatoid Arthritis	44 (5.0%)	410 (8.6%)	-0.13	40 (5.3%)	40 (5.3%)	0.00
Solid Tumor	152 (17.4%)	991 (20.8%)	-0.09	130 (17.2%)	133 (17.6%)	-0.01
Valvular Disease	176 (20.1%)	1,193 (25.1%)	-0.12	170 (22.5%)	158 (21.0%)	0.04
Weight Loss	67 (7.7%)	501 (10.5%)	-0.10	57 (7.6%)	64 (8.5%)	-0.03
Prescribing Specific Considerations						
Indications						
PSA Measurement Taken	411 (47.0%)	1,998 (42.0%)	0.10	348 (46.2%)	343 (45.5%)	0.01
Abnormal PSA	109 (12.5%)	721 (15.2%)	-0.08	95 (12.6%)	103 (13.7%)	-0.03
Slow Urinary Stream	25 (2.9%)	139 (2.9%)	0.00	23 (3.1%)	19 (2.5%)	0.03
Uroflow Study	89 (10.2%)	424 (8.9%)	0.04	84 (11.1%)	62 (8.2%)	0.10
Cystometrogram	29 (3.3%)	118 (2.5%)	0.05	25 (3.3%)	21 (2.8%)	0.03
Diagnosis of BPH	365 (41.7%)	2,043 (43.0%)	-0.03	323 (42.8%)	305 (40.5%)	0.05
Adverse Event Risks						
Orthostatic Hypotension	28 (3.2%)	276 (5.8%)	-0.12	27 (3.6%)	35 (4.6%)	-0.05
Other Hypotension	45 (5.1%)	375 (7.9%)	-0.10	41 (5.4%)	35 (4.6%)	-0.04

476
477